Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is administered by inhalation for prevention of asthma and atopic rhinitis and as eye drops for allergic conjunctivitis.
At latest update relevant published data on excretion into breast milk were not found.
Pharmacokinetic data (very low bioavailability after inhalation, orally or ophthalmic application with very low plasma levels achieved, moderately elevated molecular weight and a high protein-binding capacity) would render it rather unlikely a significant passage into breastmilk, which would also cause a poor absorption through the infant’s gut .
It is a well tolerated drug with indeed no side effects and none of them reportedly to be serious.
The small dose used and low plasma absorption of most inhaled preparations (either buccal or nasal), topically apply as ophthalmologic or dermatologic preparations, make it unlikely any passage in a significant amount into breastmilk.